½ÃÀ庸°í¼­
»óǰÄÚµå
1676228

¼¼°èÀÇ ¹«Å뼺 °©»ó¼±¿° ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2025-2033³â)

Global Silent Thyroiditis Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 139 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹«Å뼺 °©»ó¼±¿° ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 27¾ï 8,000¸¸ ´Þ·¯¿¡¼­ 2033³â 49¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇϰí, 2026-2033³âÀÇ ¿¹Ãø ±â°£ µ¿¾È 6.54%ÀÇ °ß°íÇÑ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹«Å뼺 °©»ó¼±¿° ½ÃÀåÀº °©»ó¼± Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í È¿°úÀûÀÎ °ü¸® Àü·«ÀÌ ÇÊ¿äÇÔ¿¡ µû¶ó ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹«Å뼺 °©»ó¼±¿°Àº °©»ó¼±ÀÇ ¹«Å뼺 ¿°ÁõÀ» Ư¡À¸·Î ÇÏ´Â ¹«Å뼺 °©»ó¼±¿°Àº ÀϽÃÀûÀÎ °©»ó¼± ±â´É Ç×ÁøÁõ¿¡ ÀÌ¾î °©»ó¼± ±â´É ÀúÇÏÁõÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÇ·áÁø°ú ȯÀÚµé »çÀÌ¿¡¼­ ÀÌ Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Áø´Ü µµ±¸¿Í Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå¿¡´Â °©»ó¼± ±â´É °Ë»ç, ¿µ»ó Áø´Ü, ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀÌµå ¹× °©»ó¼± È£¸£¸ó ´ëü ¿ä¹ý°ú °°Àº Ä¡·á ¿É¼Ç µî ´Ù¾çÇÑ Á¦Ç°ÀÌ ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº Áø´Ü ±â¼úÀÇ Çõ½ÅÀÌ °©»ó¼± Æò°¡ÀÇ Á¤È®¼º°ú ¼Óµµ¸¦ ³ô¿© ħ¹¬¼º °©»ó¼±¿° ½ÃÀåÀ» Å©°Ô Çü¼ºÇϰí ÀÖ½À´Ï´Ù. ÃÊÀ½ÆÄ °Ë»ç, ÇÙÀÇÇÐ °Ë»ç µî ÷´Ü ¿µ»ó Áø´Ü ±â¼úÀÇ ¹ß´Þ·Î ħ¹¬¼º °©»ó¼±¿°ÀÇ Áø´Ü ´É·ÂÀÌ Çâ»óµÇ¾î ´Ù¸¥ °©»ó¼± Áúȯ°úÀÇ °¨º°ÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ, ¿ø°Ý ÀÇ·á¿Í ¿ø°Ý ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀÇ ÅëÇÕÀ¸·Î °©»ó¼± ÁúȯÀÇ Àû½Ã Áø´Ü°ú °ü¸®°¡ ¿ëÀÌÇØÁ® ȯÀÚ°¡ ÀûÀýÇÑ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ½ÃÀåÀÌ °è¼Ó ÁøÈ­ÇÏ´Â °¡¿îµ¥, Áø´Ü ¹× Ä¡·á ¼­ºñ½º¸¦ °­È­Çϱâ À§ÇØ ¿¬±¸°³¹ßÀ» ¿ì¼±½ÃÇÏ´Â ±â¾÷ÀÌ °æÀï¿¡¼­ ¿ìÀ§¸¦ Á¡ÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

¶ÇÇÑ, ¹«Å뼺 °©»ó¼±¿° ½ÃÀåÀº °©»ó¼± °ü¸®ÀÇ ±Ù°Å Áß½ÉÀû °üÇàÀ» Àå·ÁÇÏ´Â ÀÇ·á±â°üÀÇ ÀÓ»ó °¡À̵å¶óÀΰú ±Ç°í»çÇ×ÀÇ ¿µÇâÀ» Á¡Á¡ ´õ ¸¹ÀÌ ¹Þ°í ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ °©»ó¼± ÁúȯÀÇ Áø´Ü ¹× Ä¡·á¸¦ À§ÇØ Ç¥ÁØÈ­µÈ ÇÁ·ÎÅäÄÝÀ» äÅÃÇÔ¿¡ µû¶ó ½Å·ÚÇÒ ¼ö ÀÖ°í È¿°úÀûÀÎ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä´Â °è¼Ó Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â »õ·Î¿î Ä¡·á Á¢±Ù¹ýÀ» ¸ð»öÇÏ°í ±âÁ¸ Ä¡·á¹ýÀ» °³¼±Çϱâ À§ÇÑ ¿¬±¸ ÀÌ´Ï¼ÅÆ¼ºê¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ȯÀÚ Áß½ÉÀÇ Ä¡·á¿Í »îÀÇ Áú¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¹«Å뼺 °©»ó¼±¿°ÀÇ È¿°úÀûÀÎ °ü¸® Àü·«¿¡ ´ëÇÑ ¿ä±¸°¡ È®´ëµÉ °ÍÀ̸ç, ÀÓ»óÀû ¿ä±¸¿¡ ºÎÇÕÇÏ´Â Á¦Ç°À» Á¦°øÇÏ´Â ±â¾÷Àº ÀÌ Áß¿äÇÑ ½ÃÀå¿¡¼­ ¼º°øÀ» °ÅµÑ ¼ö ÀÖÀ» °ÍÀÔ´Ï´Ù.

´ç»çÀÇ º¸°í¼­´Â °í°´¿¡°Ô ´Ù¾çÇÑ »ê¾÷ ¹× ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÌ°í ½Ç¿ëÀûÀÎ ÅëÂû·ÂÀ» Á¦°øÇϱâ À§ÇØ ¼¼½ÉÇÏ°Ô ÀÛ¼ºµÇ¾ú½À´Ï´Ù. °¢ º¸°í¼­¿¡´Â ½ÃÀå »óȲÀ» ¿ÏÀüÈ÷ ÀÌÇØÇϱâ À§ÇÑ ¸î °¡Áö Áß¿äÇÑ ¿ä¼Ò°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

½ÃÀå °³¿ä: ½ÃÀå °³¿ä: Á¤ÀÇ, ºÐ·ù, »ê¾÷ ÇöȲÀ» Æ÷ÇÔÇÑ »ó¼¼ÇÑ ½ÃÀå ¼Ò°³.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ: ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ¹× °úÁ¦¸¦ »ó¼¼ÇÏ°Ô ºÐ¼®ÇÕ´Ï´Ù. ÀÌ ¼½¼Ç¿¡¼­´Â ±â¼ú ¹ßÀü, ±ÔÁ¦ º¯È­, »õ·Î¿î Æ®·»µå µîÀÇ ¿äÀÎÀ» °ËÅäÇÕ´Ï´Ù.

¼¼ºÐÈ­ ºÐ¼® : Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ª µîÀÇ ±âÁØ¿¡ µû¶ó ½ÃÀåÀ» ¸íÈ®ÇÑ ºÎ¹®À¸·Î ºÐ·ùÇÕ´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ °¢ ºÎ¹®ÀÇ ¼º°ú¿Í ÀáÀç·ÂÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

°æÀï»óȲ: ½ÃÀå Á¡À¯À², Á¦Ç° Æ÷Æ®Æú¸®¿À, Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê, À繫½ÇÀû µî ÁÖ¿ä ½ÃÀå ÁøÀÔ±â¾÷¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ Æò°¡. ÁÖ¿ä ±â¾÷µéÀÌ Ã¤ÅÃÇϰí ÀÖ´Â °æÀï ¿ªÇÐ ¹× ÁÖ¿ä Àü·«¿¡ ´ëÇÑ °íÂûÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

½ÃÀå ¿¹Ãø : °ú°Å µ¥ÀÌÅÍ¿Í ÇöÀç ½ÃÀå »óȲÀ» ¹ÙÅÁÀ¸·Î ÀÏÁ¤ ±â°£ µ¿¾È ½ÃÀå ±Ô¸ð¿Í ¼ºÀå Ãß¼¼¸¦ ¿¹ÃøÇÕ´Ï´Ù. ¿©±â¿¡´Â Á¤·®Àû ºÐ¼®°ú ¹Ì·¡ ½ÃÀå ±ËÀûÀ» ³ªÅ¸³»´Â ±×·¡ÇÁ Ç¥½Ã°¡ Æ÷ÇԵ˴ϴÙ.

Áö¿ª ºÐ¼® : Áö¿ªº° ½ÃÀå ¼º°ú¸¦ Æò°¡Çϰí ÁÖ¿ä ½ÃÀå ¹× Áö¿ª µ¿ÇâÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. Áö¿ª ½ÃÀå ¿ªÇÐ ¹× ºñÁî´Ï½º ±âȸ¸¦ ÀÌÇØÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

»õ·Î¿î Æ®·»µå¿Í ±âȸ: ÇöÀç ½ÃÀå µ¿Çâ°ú »õ·Î¿î ½ÃÀå µ¿Çâ, ±â¼ú Çõ½Å, ÀáÀçÀû ÅõÀÚ ´ë»ó ºÎ¹®À» ½Äº°ÇÕ´Ï´Ù. ¹Ì·¡ ½ÃÀå °³Ã´ ¹× ¼ºÀå Àü¸Á¿¡ ´ëÇÑ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ÇöȲ

Á¦3Àå ¹«Å뼺 °©»ó¼±¿° »ê¾÷ ºÐ¼®

  • ¼­·Ð - ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • »ê¾÷ µ¿Çâ
  • PorterÀÇ Five Forces ºÐ¼®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿ø·á ºÐ¼®
    • ¿ø·á ¸®½ºÆ®
    • ¿ø·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿ø·á °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ¹«Å뼺 °©»ó¼±¿° ½ÃÀå ºÐ¼® : Áø´Ü °Ë»çº°

  • Áø´Ü °Ë»çº° °³¿ä
  • Áø´Ü °Ë»çº° °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • °©»ó¼± ±â´É °Ë»ç
  • °©»ó¼± Ç×ü °Ë»ç
  • ÃÊÀ½ÆÄ °Ë»ç
  • »ý°Ë

Á¦6Àå ¼¼°èÀÇ ¹«Å뼺 °©»ó¼±¿° ½ÃÀå ºÐ¼® : Ä¡·áº°

  • Ä¡·áº° °³¿ä
  • Ä¡·áº° °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • Ç׿°ÁõÁ¦
  • Ç׿ì¿ïÁ¦
  • È£¸£¸ó ´ëü¿ä¹ý
  • ¹æ»ç¼º ·ÎÁø Ä¡·á

Á¦7Àå ¼¼°èÀÇ ¹«Å뼺 °©»ó¼±¿° ½ÃÀå ºÐ¼® : ȯÀÚ À¯Çüº°

  • ȯÀÚ À¯Çüº° °³¿ä
  • ȯÀÚ À¯Çüº° °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • ¼ºÀÎ
  • ¼Ò¾Æ
  • ÀÓ»êºÎ
  • »êÈÄ ¿©¼º

Á¦8Àå ¼¼°èÀÇ ¹«Å뼺 °©»ó¼±¿° ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­·Ð
  • ºÏ¹ÌÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ºÐ¼®°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ºÐ¼®°ú ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ºÐ¼®°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ºÐ¼®°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ºÐ¼®°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º° ¸®½ºÆ®
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ¹«Å뼺 °©»ó¼±¿° ±â¾÷ °æÀï ±¸µµ

  • ¹«Å뼺 °©»ó¼±¿° ½ÃÀå °æÀï
  • Á¦ÈÞ, Çù¾ö ¹× °è¾à
  • ÀμöÇÕº´(M&A)
  • ½ÅÁ¦Ç° ¹ß¸Å
  • ±âŸ °³¹ß

Á¦10Àå ±â¾÷ °³¿ä

  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • AstraZeneca Pic
  • GiaxoSmilhiine Plc
  • Bayer AG
  • Sanofi S.A.
  • Novo Nordisk A'S
  • Boeing Ingelheim GmbH
  • Novartis AG
  • Bof Laboralores Inc.
  • Pizer Inc.
  • Merck & Co Inc.
  • Ef Lily And Company
  • Amgen Inc.
  • Johnson & Johnson
  • Teva Phamaceutial Industries Ld
LSH 25.04.10

Global Silent Thyroiditis Market size is anticipated to grow from USD 2.78 Billion in 2024 to USD 4.92 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 6.54% during the forecast period of 2026 to 2033.

The Silent Thyroiditis market is set for growth, driven by the increasing recognition of thyroid disorders and the need for effective management strategies. Silent thyroiditis, characterized by painless inflammation of the thyroid gland, can lead to transient hyperthyroidism followed by hypothyroidism. As awareness of this condition grows among healthcare providers and patients, the demand for diagnostic tools and therapeutic options is expected to rise. The market encompasses a range of products, including thyroid function tests, imaging modalities, and treatment options such as corticosteroids and thyroid hormone replacement therapy.

Technological advancements are significantly shaping the Silent Thyroiditis market, with innovations in diagnostic technologies enhancing the accuracy and speed of thyroid assessments. The development of advanced imaging techniques, such as ultrasound and nuclear medicine scans, is improving the ability to diagnose silent thyroiditis and differentiate it from other thyroid disorders. Additionally, the integration of telemedicine and remote monitoring solutions is facilitating timely diagnosis and management of thyroid conditions, ensuring that patients receive appropriate care. As the market continues to evolve, companies that prioritize research and development to enhance their diagnostic and therapeutic offerings will likely gain a competitive edge.

Moreover, the Silent Thyroiditis market is increasingly influenced by clinical guidelines and recommendations from healthcare organizations that promote evidence-based practices in thyroid management. As healthcare systems adopt standardized protocols for diagnosing and treating thyroid disorders, the demand for reliable and effective solutions will continue to rise. This trend is driving investment in research initiatives aimed at exploring novel treatment approaches and improving existing therapies. As the focus on patient-centered care and quality of life grows, the need for effective management strategies for silent thyroiditis will expand, positioning companies that align their offerings with clinical needs for success in this vital market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Diagnostic Test

  • Thyroid Function Tests
  • Thyroid Antibodies Tests
  • Ultrasound
  • Biopsy

By Treatment

  • Antiinflammatory Medications
  • Anticepressants
  • Hormone Replacement Therapy
  • Radioactive lodine Treatment

By Patient Type

  • Adults
  • Children
  • Pregnant Women
  • Postpartum Women
  • COMPANIES PROFILED
  • AstraZeneca pic
  • GiaxoSmilhiine plc
  • Bayer AG
  • Sanofi S.A.
  • Novo Nordisk A'S
  • Boeing Ingelheim GmbH
  • Novartis AG
  • bof Laboralores Inc.
  • Pizer Inc.
  • Merck & Co Inc.
  • Ef Lily and Company
  • Amgen Inc.
  • Johnson & Johnson
  • Teva Phamaceutial Industries Ld.
  • The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. SILENT THYROIDITIS INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porters Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Diagnostic Test
    • 3.7.2 Market Attractiveness Analysis By Treatment
    • 3.7.3 Market Attractiveness Analysis By Patient Type
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL SILENT THYROIDITIS MARKET ANALYSIS BY DIAGNOSTIC TEST

  • 5.1. Overview By Diagnostic Test
  • 5.2. Historical and Forecast Data Analysis By Diagnostic Test
  • 5.3. Thyroid Function Tests Historic and Forecast Sales By Regions
  • 5.4. Thyroid Antibodies Tests Historic and Forecast Sales By Regions
  • 5.5. Ultrasound Historic and Forecast Sales By Regions
  • 5.6. Biopsy Historic and Forecast Sales By Regions

6. GLOBAL SILENT THYROIDITIS MARKET ANALYSIS BY TREATMENT

  • 6.1. Overview By Treatment
  • 6.2. Historical and Forecast Data Analysis By Treatment
  • 6.3. Antiinflammatory Medications Historic and Forecast Sales By Regions
  • 6.4. Anticepressants Historic and Forecast Sales By Regions
  • 6.5. Hormone Replacement Therapy Historic and Forecast Sales By Regions
  • 6.6. Radioactive lodine Treatment Historic and Forecast Sales By Regions

7. GLOBAL SILENT THYROIDITIS MARKET ANALYSIS BY PATIENT TYPE

  • 7.1. Overview By Patient Type
  • 7.2. Historical and Forecast Data Analysis By Patient Type
  • 7.3. Adults Historic and Forecast Sales By Regions
  • 7.4. Children Historic and Forecast Sales By Regions
  • 7.5. Pregnant Women Historic and Forecast Sales By Regions
  • 7.6. Postpartum Women Historic and Forecast Sales By Regions

8. GLOBAL SILENT THYROIDITIS MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE SILENT THYROIDITIS COMPANIES

  • 9.1. Silent Thyroiditis Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF SILENT THYROIDITIS INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. AstraZeneca Pic
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. GiaxoSmilhiine Plc
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. Bayer AG
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. Sanofi S.A.
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. Novo Nordisk A'S
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. Boeing Ingelheim GmbH
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. Novartis AG
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. Bof Laboralores Inc.
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments
  • 10.11. Pizer Inc.
    • 10.11.1 Company Overview
    • 10.11.2 Company Revenue
    • 10.11.3 Products
    • 10.11.4 Recent Developments
  • 10.12. Merck & Co Inc.
    • 10.12.1 Company Overview
    • 10.12.2 Company Revenue
    • 10.12.3 Products
    • 10.12.4 Recent Developments
  • 10.13. Ef Lily And Company
    • 10.13.1 Company Overview
    • 10.13.2 Company Revenue
    • 10.13.3 Products
    • 10.13.4 Recent Developments
  • 10.14. Amgen Inc.
    • 10.14.1 Company Overview
    • 10.14.2 Company Revenue
    • 10.14.3 Products
    • 10.14.4 Recent Developments
  • 10.15. Johnson & Johnson
    • 10.15.1 Company Overview
    • 10.15.2 Company Revenue
    • 10.15.3 Products
    • 10.15.4 Recent Developments
  • 10.16. Teva Phamaceutial Industries Ld
    • 10.16.1 Company Overview
    • 10.16.2 Company Revenue
    • 10.16.3 Products
    • 10.16.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦